Forensic Science International
May 20, 2011
Jennifer L. Pilgrim, Dimitri Gerostamoulos, Noel Woodford et al.
44 citations
The use of MDMA (ecstasy) in Australia is a widespread and growing problem, promoting acute toxicity and disease which can lead to premature death in users. We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity. Despite the highly reported toxicity of this drug combination, there are...
The Open Forensic Science Journal
May 12, 2011
Steven B. Karch
31 citations
In less than 50 years the number of MDMA (3,4-Methylenedioxymethamphetamine or Ecstasy) users in the United States has gone from zero to nearly three million.For all of its popularity, very little is known about MDMA's probable mechanism of action, or the mechanisms by which it causes death and disability.Even less is known about this drug's checkered past, including dangerous plans by various...
Neuropsychopharmacology
May 11, 2011
Janelle H. P. van Wel, Kim P. C. Kuypers, Eef L. Theunissen et al.
52 citations
3,4-Methylenedioxymethamphetamine (MDMA) or 'ecstasy' has been associated with memory deficits during abstinence and intoxication. The human neuropharmacology of MDMA-induced memory impairment is unknown. This study investigated the role of 5-HT(2A) and 5-HT(1A) receptors in MDMA-induced memory impairment. Ketanserin is a 5-HT(2A) receptor blocker and pindolol a 5-HT(1A) receptor blocker. It...
Journal of Neuroscience
May 11, 2011
Philippe Huot, Tom H. Johnston, Katie D. Lewis et al.
83 citations
l -3,4-Dihydroxyphenylalanine ( l -DOPA) is the most effective treatment for Parkinson's disease, but long-term l -DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions...
Brain Research
May 4, 2011
Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats.
Journal of Pharmacy Technology
May 1, 2011
Matthew L. Banks, Jon E. Sprague
Objective: To evaluate the scientific rationale and efficacy of pharmacologic and nonpharmacologic treatments for sympathomimetic-induced hyperthermia and related sequelae. Data Sources: Literature was accessed through MEDLINE (1940-September 2010) using the terms MDMA [3,4-methylenedioxymethamphetamine], methamphetamine, toxicity, and hyperthermia. In addition, reference citations from...
Clinical Pharmacokinetics
May 1, 2011
Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Neuropsychopharmacology
May 2011
Amy L Bauernfeind, Mary S Dietrich, Jennifer U Blackford et al.
The serotonergic neurotoxin, 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy), is a highly popular recreational drug. Human recreational MDMA users have neurocognitive and neuropsychiatric impairments, and human neuroimaging data are consistent with animal reports of serotonin neurotoxicity. However, functional neuroimaging studies have not found consistent effects of MDMA on brain...
Journal of Analytical Toxicology
May 1, 2011
Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H Drummer
36 citations
The increasing use of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and tendency of users to combine MDMA with pharmaceutical agents (especially serotonergic medication) warrants a thorough understanding of MDMA's toxicity profile and potential for drug interactions. This study examined the involvement of MDMA and concurrently administered pharmaceutical drugs in cases reported to the...
European Journal of Pharmacology
April 28, 2011
Pamela B. Yang, Kristal D. Atkins, Nachum Dafny
42 citations
The psychostimulants amphetamine and methylphenidate (MPD / Ritalin) are the drugs most often used to treat attention deficit hyperactivity disorder (ADHD). In addition, students of all ages take these drugs to improve academic performance but also abuse them for pleasurable enhancement. In addition, other psychostimulants such 3,4 methylenedioxymethamphetamine (MDMA / ecstasy) are used /...
British Journal of Pharmacology
April 21, 2011
Daniel José Barbosa, João Paulo Capela, Jorge M.A. Oliveira et al.
60 citations
BACKGROUND AND PURPOSE: 3,4-Methylenedioxymethamphetamine (MDMA or 'Ecstasy') is a worldwide major drug of abuse known to elicit neurotoxic effects. The mechanisms underlying the neurotoxic effects of MDMA are not clear at present, but the metabolism of dopamine and 5-HT by monoamine oxidase (MAO), as well as the hepatic biotransformation of MDMA into pro-oxidant reactive metabolites is thought...
European Journal of Pharmacology
April 9, 2011
Pharmacodynamic interactions between MDMA and concomitants in MDMA tablets on extracellular dopamine and serotonin in the rat brain.
Forensic Science International
April 8, 2011
New "party pill" components in New Zealand: the synthesis and analysis of some β-ketone analogues of 3,4-methylenedioxymethamphetamine (MDMA) including βk-DMBDB (β-ketone-N,N-dimethyl-1-(1,3-benzodioxol-5-yl)-2-butanamine).
Health Risk & Society
April 8, 2011
Jeremy W. Collins
4 citations
In February 2009, the UK government's Advisory Council on the Misuse of Drugs (ACMD) published a review of MDMA (ecstasy) which recommended a reclassification from the highest class A to the ‘intermediate category’ class B, on the basis of a review of recent scientific research. This became a matter of news attention alongside a recent journal article by Professor David Nutt, the chairman of...
Behavioural Pharmacology
April 8, 2011
Adam Stewart, Russell Riehl, Keith Wong et al.
66 citations
3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') is a potent psychedelic drug inducing euphoria and hypersociability in humans, as well as hyperactivity and anxiety in rodents. Adult zebrafish (Danio rerio) have become a widely used species in neurobehavioral research. Here, we explore the effects of a wide range (0.25-120 mg/l) of acute MDMA doses on zebrafish behavior in the novel tank...
Journal of Pharmacology and Experimental Therapeutics
April 8, 2011
Michael B. Gatch, Michael J. Forster, Aaron Janowsky et al.
42 citations
The abuse liability profile of three synthetic hallucinogens, N,N-diisopropyltryptamine (DIPT), 5-N,N-diethyl-5-methoxytryptamine (5-MeO-DET), and 5-methoxy-α-methyltryptamine (5-MeO-AMT), was tested in rats trained to discriminate hallucinogenic and psychostimulant compounds, including cocaine, methamphetamine, 3,4-methylenedioxymethylamphetamine (MDMA), lysergic acid diethylamide (LSD),...
Psychopharmacology
April 2011
Amanda M George, Tim D Windsor, Bryan Rodgers
Whether the reported poorer mental health of ecstasy users is due to a bias in endorsement of somatic symptoms has been postulated, but rarely examined. The purpose of this study is to investigate whether levels of ecstasy use were associated with differential probabilities of endorsing somatic mental health symptoms. Current ecstasy users aged 24-30 years (n = 316) were identified from a...
The FASEB Journal
April 1, 2011
Kevin S. Murnane, Leonard L. Howell
3,4-methylenedioxymethamphetamine (MDMA) is a substituted amphetamine derivative that is widely abused as the street drug “ecstasy”. Despite its high abuse liability, the neuropharmacology of MDMA remains poorly understood. In the present study, functional magnetic resonance imaging (fMRI) was used in fully conscious rhesus monkeys to characterize the neuroactivational effects of MDMA and its...
Journal of Psychosocial Nursing and Mental Health Services
April 1, 2011
Susanne A. Fogger
2 citations
After years of declining use in the United States, youth consumption of ecstasy has increased significantly. Although ecstasy (3, 4-methylenedioxymethamphetamine) is known to be a drug with detrimental effects, users view the drug as a safe and attractive social lubricant. To update and clarify misperceptions, this article reviews current evidence regarding ecstasy's side effects and risks and...
Psychopharmacology
April 1, 2011
Shahaf Edut, Vardit Rubovitch, Shaul Schreiber et al.
36 citations
The use of ecstasy (MDMA) among young adults has dramatically increased over the years. Since MDMA may impair the users' driving ability, the risk of being involved in a motor vehicle accident (MVA) is notably increased. Minimal traumatic brain injury (mTBI) a common consequence of MVAs-produces short- and long-term physical, cognitive, and emotional impairments. To investigate the effects of...